a) Significant different from CISH ratio in a two tailed, paired t-test (N = 348, P < 0.001) b) Significant different from CISH ratio in a two tailed, paired t-test (N = 350, P = 0.001) c) Not ...
The European Patent Office (EPO) has granted WEHI a patent for CISH knockout (KO) in Natural Killer (NK) cells which is exclusively licensed to ONK Therapeutics for cell immunotherapy purposes, giving ...
Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC): Interim safety analysis.
Skilled Staff – Agri-professionals who should be Graduate/ Post Graduate in Agriculture/Horticulture with five years of experience in this sector. Project Assistant ...
GALWAY, Ireland & SAN DIEGO--(BUSINESS WIRE)--ONK Therapeutics Ltd, an innovative NK cell therapy company, today announced that the US Patent and Trademark Office (USPTO) has granted its licensed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results